Moffitt
Welcome,         Profile    Billing    Logout  
 16 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Druta, Mihaela
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SUNRISELMS, NCT05269355: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics
Leiomyosarcoma
06/24
06/24
SPEARHEAD-1, NCT04044768: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
Checkmark From SPEARHEAD 1 trial for synovial sarcoma or myxoid/round cell liposarcoma
More
Recruiting
2
120
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune
Synovial Sarcoma, Myxoid Liposarcoma
10/21
04/38
NCT02923778: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Active, not recruiting
2
40
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
12/24
12/24
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
12/24
12/24
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/24
BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Recruiting
1/2
420
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/25
12/25
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
GSK adoptive cell therapy
GlaxoSmithKline
Neoplasms
04/32
04/32
Creelan, Ben
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated
2
1
Europe
Biological: ATL001
Achilles Therapeutics UK Limited
Melanoma, Advanced Non Small Cell Lung Cancer
10/23
10/23
NCT05681780: Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Recruiting
1/2
20
US
Tumor-infiltrating Lymphocytes (TIL), TIL, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2), IL2
H. Lee Moffitt Cancer Center and Research Institute
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
07/25
07/25
NCT03215810: Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed
1
20
US
Tumor-infiltrating Lymphocytes (TIL), TIL, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2), IL2, Proleukin®
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Inc., Stand Up To Cancer, Iovance Biotherapeutics, Inc.
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
02/21
06/23
Schneider, Cheyenne
MINOTAUR, NCT05147350: Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

Active, not recruiting
1
36
Europe, Canada, US
RP-6306 (oral PKMYT1 inhibitor), FOLFIRI
Repare Therapeutics
Advanced Solid Tumor
07/26
11/26

Download Options